Healthcare providers should report suspected Zika virus disease cases to their state, local, or territorial health department to facilitate diagnosis and mitigate risk of local transmission. State, local, and territorial health departments should report laboratory-confirmed and probable cases to CDC.
The following is a summary of CDC testing protocols. For detailed protocols and information, the CDC resource pages can be found in the Learn More – Primary Sources section below
Symptomatic individuals with possible exposure to Zika virus
Testing for Zika virus is available using molecular and serological assays. Typical symptoms include acute onset of fever, with maculopapular rash, arthralgia, myalgia, headache, conjunctivitis. Differential diagnosis of such symptoms is broad and include group A strep, rubella, measles and other viral diseases. Therefore, to identify those at risk for Zika virus, it is essential to take a travel and sexual history of all patients presenting with the above symptoms and to stay current with CDC updates as to high Zika virus transmission areas.
Tests for Zika virus include the following
Molecular Testing: Triplex Real-time RT-PCR Assay (rRT-PCR)
Antibody Detection Methods: Zika virus IgM
PRNT (Plaque Reduction Neutralization Test) to confirm antibodies
Please log in to access ObGFirst and the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst